EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 23 May 2019

Cancer medicines: Why we must strengthen the link between price and value

A blog by Brian Cuffel, Vice President and Head of Oncology Market Access, Bayer

A WHO Technical Report on pricing of cancer medicines has raised questions for its unorthodox view of value-based pricing. The report is critical of what it sees as industry over-investment in cancer medicines R&D and what is portrayed as excessive return on investment.

For economists and others involved in policy discussion on drug price regulation, this is more than surprising. Not only is this thinking out of step with the wider trend towards value-based healthcare, it takes a selective view of pricing and builds its case on an assumption that the successes enjoyed by the oncology sector were entirely foreseeable 30 years ago. Of course, that’s not how it works. Read more

News

From votes to vision
23 May 2019

The health of the EU’s citizens depends on all of us - policy-makers, healthcare professionals, civil society and industry.... Read more

Blog

Gene therapy for liver disease: The power of protecting new ideas (Guest blog)
23 May 2019 - Jean-Philippe Combal

The IP environment in Europe has helped companies like Vivet turn ideas into assets that create value, jobs and address... Read more

Videos

Stronger Together: Joining forces to fast-track results
Collaboration makes us stronger. Together we can transform the lives of patients - it is why #WeWontRest. Read the full... Read more

European Excellence: Making the EU a world leader in medical R&D
Collaboration makes us stronger. Together we can transform the lives of patients - it is why #WeWontRest. Read more

Health For All: Bringing innovative health solutions to all patients
#WeWontRest until we bring innovative health solutions to all patients. Read more

Protect The Spark
Every new treatment or cure starts with the spark of an idea. That spark has to be nurtured and cared for through the... Read more

Events

EFPIA 2019 Annual Conference
27 June 2019 (Radisson Blu Royal Hotel, Brussels, Belgium)

Making connections can advance patient care and support the European economy at a time of significant change and challenge... Read more

EFPIA Oncology Data Summit: Unleashing the potential of data to improve cancer care
18 June 2019 (Brussels)

The Summit will bring together cancer and data players from around Europe to actively participate in identifying the... Read more

IMI Stakeholder Forum 2019
12 June 2019 (Royal Museums of Fine Arts of Belgium)

Brain health and disease in the digital era - 2020 and beyond Read more

FT Digital Health Summit 2019
18 June 2019 (Berlin)

Collaboration is key to effectively harnessing digital disruption to ease the strain and deliver more adaptable and... Read more

Building a healthier future for Europe

Manifesto: Building a healthier future for Europe
06 September 2018 (Publications)

Together we can transform the lives of patients - it is why #WeWontRest Read more

What we are reading

Type 2 diabetes and deadly liver disease risk highlighted by study
On 22 May 2019 (Diabetes Times)

People with type 2 diabetes and liver disease are more than twice as likely to develop aggressive liver disease, an... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu